Inomagen Therapeutics is developing a non-viral gene therapy to address the underlying mechanisms of atrial fibrillation. Their single-dose, minimally invasive treatment aims to correct cellular dysfunctions, offering a durable solution for patients with this cardiac arrhythmia.
Funding
Funding not disclosed
Founders
Product
Problem
Atrial fibrillation (AFib) is the most prevalent sustained cardiac arrhythmia, affecting a significant and growing portion of the population. Current therapeutic interventions often manage symptoms rather than address the underlying pathological mechanisms of the disease, leading to suboptimal outcomes for many patients.
Solution
Inomagen Therapeutics is developing a novel, non-viral gene therapy designed to target the fundamental mechanisms driving atrial fibrillation. This platform utilizes a single-dose, minimally invasive administration approach to correct the cellular and molecular dysfunctions associated with AFib. The therapy is backed by over a decade of research and validated in multiple preclinical models, demonstrating its potential to offer a transformative treatment option. By addressing the root cause of AFib, Inomagen aims to provide a durable and effective solution for patients with this complex cardiac condition.
Target Audience
The primary target audience includes patients diagnosed with atrial fibrillation, cardiologists, electrophysiologists, and pharmaceutical or biotechnology companies seeking strategic partnerships for advanced cardiovascular therapies.
Features
- Non-viral gene delivery platform for therapeutic intervention in atrial fibrillation.
- Single-dose administration for improved patient compliance and reduced treatment burden.
- Minimally invasive procedure designed for enhanced safety and tolerability.
- Proprietary technology targeting the underlying mechanisms of AFib, not just symptomatic relief.
- Extensive preclinical validation across multiple models demonstrating efficacy and safety.
- Robust intellectual property estate licensed from Northwestern University.